XaTek
The First Point-of-Care Diagnostic for Hemophilia & an Emerging Class of Anti-Coagulants

Trials

Clinical Investigation

XaTek has completed numerous successful feasibility studies on the ClotChip™ sensor.

Pilot Studies

1)          Phase I Clinical Trial

ClotChip™ Sensitivity in Target Specific oral Anticoagulants

The U.S. Department of Veterans Affairs, Cleveland, OH

September 2017 – July 2018 ; N=176

Assessment of whole blood coagulation with a microfluidic dielectric sensor published in Journal of Thrombosis and Haemostasis, 16: 2050–205

 

2)          Phase I Clinical Trial

ClotChip™ Sensitivity in Hemophilia - In Vivo & Ex Vivo analyses

University Hospitals of Cleveland – Rainbow Babies & Children Hospital, Cleveland, OH

Status: active enrollment ; N = 100

3)          Phase 2 Clinical Trial

 ClotChip™ correlation to peak-trough blood concentration in both apixaban & rivaroxaban subjects

The U.S. Department of Veterans Affairs, Cleveland, OH

 Status: active enrollment ; N = 24